Combining PDE4 and Statin Inhibitors for Synergistic Anti-Inflammatory Pulmonary Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory pulmonary diseases like asthma and COPD are limited in effectiveness due to their reliance on targeting single mediators or cell types, leading to unsatisfactory results, and there is a need for a combination therapy that leverages different therapeutic pathways to enhance treatment outcomes.
Innovation Solution
A combination of a PDE4 inhibitor, such as Roflumilast, and an HMG-CoA reductase inhibitor, such as Simvastatin or Atorvastatin, is used to create a pharmaceutical composition or kit that potentiates anti-inflammatory effects, offering a synergistic approach for the preventive or curative treatment of inflammatory pulmonary diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single mediator or cell type targeting is used in current treatments, then treatment simplicity is maintained, but treatment effectiveness deteriorates due to limited success in addressing multifactorial pathologies
Solution Approach 1:
The patent combines two distinct therapeutic agents with different mechanisms of action: a PDE4 inhibitor (roflumilast) that targets inflammatory mediator degradation, and an HMG-CoA reductase inhibitor (statin) that targets cholesterol synthesis and has anti-inflammatory properties. This merging of two separate treatment pathways into a single combination therapy addresses the multifactorial nature of inflammatory pulmonary diseases more effectively than single-target therapies, while maintaining practical administrability through fixed-dose combination pills.
2Reliability
If combination therapy with multiple agents is used, then treatment effectiveness improves by addressing multifactorial pathologies, but treatment complexity increases
Solution Approach 1:
The patent merges two separate medications into a single fixed-dose combination product containing both the PDE4 inhibitor and HMG-CoA reductase inhibitor in one pill. This approach maintains the therapeutic benefits of combination therapy while simplifying the treatment regimen for patients, thereby improving ease of operation and treatment compliance without requiring patients to take multiple separate medications.
Solution Approach 2:
The combination therapy product serves multiple functions simultaneously: it provides anti-inflammatory effects through PDE4 inhibition, addresses lipid metabolism and has additional anti-inflammatory benefits through statin action, and simplifies the treatment regimen. This multi-functionality in a single product improves ease of operation by consolidating what would otherwise require multiple separate treatment actions.
3Reliability
If higher doses of single agents are used to achieve synergistic effects, then treatment effectiveness improves, but side effects increase
Solution Approach 1:
The patent utilizes parameter changes by combining two agents that work through different mechanisms at lower individual doses to achieve synergistic therapeutic effects. The PDE4 inhibitor and HMG-CoA reductase inhibitor have complementary anti-inflammatory pathways that, when combined, produce greater efficacy than either agent alone at high doses, while maintaining lower individual doses that reduce the risk of dose-dependent side effects from each medication.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined use of PDE4 and HMG-CoA reductase inhibitors provides a synergistic efficacy superior to either component alone, potentially reducing side effects, lowering required doses, and improving treatment compliance, while effectively addressing the multifactorial pathologies of inflammatory pulmonary diseases like asthma and COPD.
Implementation Method 1
Cyclic nucleotide phosphodiesterase (PDE) inhibitors, particularly inhibitors of type 4 (PDE4), are useful in the treatment of a variety of allergic and inflammatory diseases
Implementation Method 2
They reduce cholesterol levels through competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the key enzyme that regulates cholesterol synthesis
Implementation Method 3
the combined use of a PDE4 inhibitor and a HMG-CoA reductase inhibitor potentiates the anti-inflammatory effect of either component alone
Data Source
AI summary
The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.